Twenty-Year Veteran of Biotechnology Industry Joins Sofinnova Ventures
Harold E. Selick, PhD, an Alumnus of Affymax, Protein Design Labs and Camitro,
Will Increase Sofinnova Venture's Investment Activity in Biotech
SAN FRANCISCO, May 22 /PRNewswire/ -- Sofinnova Ventures, a venture firm investing in early stage information technology and life sciences companies, today announced that Harold E. "Barry" Selick, PhD has joined the firm as a Venture Partner. Selick has held scientist and senior executive positions with several successful biotechnology companies, including Affymax, Protein Design Labs, Anergen and Camitro. With the addition of Selick, Sofinnova Ventures will increase its investment activity in biotech platform and drug discovery companies. The firm's investments in biotechnology include AlgoRx, Actelion, David Pharmaceuticals, Exhale Therapeutics, KaloBios, InterMune Pharmaceuticals, Novocea and Seattle Genetics. "We are bringing Barry on board to give even more strength to our life science investing," commented Michael Powell, PhD, a Managing Director of Sofinnova Ventures. "His scientific expertise will enable him to distinguish the most promising biotechnology companies for Sofinnova to invest in, and his strong operational background will make him perfectly suited to take on interim management roles for our young start-ups." "I am very excited to be joining such an accomplished team of investors and entrepreneurs and am looking forward to contributing my own experience in helping to strengthen and expand Sofinnova's portfolio of innovative and inspiring biotechnology ventures," said Selick. Selick co-founded Camitro in January 1999. As President and CEO of the company, he recruited a world-class team of scientists and entrepreneurs, oversaw the creation and commercialization of Camitro's technology for pharmaceutical drug discovery, established two corporate sites in Menlo Park, California and Cambridge, the United Kingdom, and initiated and led the Camitro team in negotiations that resulted in its acquisition by the drug discovery company Arqule in 2001 for $95 million. Prior to Camitro, Selick was Vice President, Research for Affymax Research Institute, the wholly owned drug discovery technology development center for Glaxo Wellcome. He directed activities in combinatorial chemistry-based drug discovery, with particular emphasis on the development of technologies for improving the process of lead optimization. He was also Senior Scientist, Head of Molecular Biology at Anergen, Inc. (acquired by Corixa) and a Staff Scientist at Protein Design Labs, where he was co-inventor of the technology underlying the creation of fully humanized antibodies. He applied this technology to the creation of the "Smart anti-TAC" antibody, which was successfully developed and commercialized by Roche as "Zenapax", for treating kidney transplant rejection. Selick was a Damon Runyon-Walter Winchell Cancer Fund Fellow with Professor Bruce Alberts (currently President of the National Academy of Sciences) and an American Cancer Society Fellow at the University of California, San Francisco, School of Medicine. He earned a Ph.D. in Biology and a BA in Biophysics from the University of Pennsylvania. About Sofinnova Ventures Sofinnova Ventures is part of a global organization with offices in France and the United States. With a U.S. base in San Francisco, Sofinnova was founded in 1972 and is one of the oldest venture capital firms. The firm emphasizes a diversified investment strategy through financing seed and early-stage companies in the communications, information technology and life science sectors. Sofinnova's mission is to create value by providing entrepreneurs with the collective resources, experience and network necessary to build early-stage companies into profitable businesses. With strong ties to Europe's leading financial, technology and venture organizations, Sofinnova helps U.S. companies rapidly enter Europe's growing markets, and European companies to develop a strong presence in U.S. markets. Historically, Sofinnova Ventures has been associated with leading companies such as Biogen, Collagen, Genentech, Printronix, Tandon and Tandem Computers. More recently, Sofinnova has invested in Actelion, Aviron, InterMune Pharmaceuticals, Millennium Pharmaceuticals, Phone.com, Premisys, Nishan Systems and Tumbleweed. For more information, visit www.sofinnova.com. Tell Us What You Think -- Click Here http://tbutton.prnewswire.com/prn/11690X38669832
SOURCE Sofinnova Ventures
More by this Source
Sofinnova Promotes Jennifer James to Partner
Jul 24, 2013, 06:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.